Gyeongsang Pharmaceutical(14,750 -0.34%)Announced on the 4th that it has signed consecutive contracts for consignment production (CMO) and export of antibiotic raw materials with two Swiss pharmaceutical companies. It is an explanation that it will enter the advanced antibiotic market such as the US and Europe in earnest.
Kyungsang Pharmaceutical recently signed a contract for the consignment production of ceftobiprole, a new cepha-based antibiotic drug, with Basilia, Switzerland. Basilia is a pharmaceutical company that develops antibiotics, antifungal and anticancer drugs by spun off from Roche, a multinational pharmaceutical company. Developed ceftobiprole.
With this contract, Kyongsang Pharmaceutical will manufacture and supply ingredients for ceftobiprole. Basilia manufactures its products and sells them to Europe, Asia and South America. After completing Phase 3 clinical trials of ceftobiprole currently in progress in the United States, Bacillia plans to sell products made from Kwangwon Pharmaceutical’s raw materials in 2023.
An export contract was signed with Stragen, Switzerland, for cephalotaxime sodium. Antibiotics manufactured from raw materials exported by Kyongsang Pharmaceutical will be sold in eight countries in North America and Europe, including Canada, Germany, Norway.
Kyongsang Pharmaceutical is actively engaged in CMO business with global pharmaceutical companies as well as CDMO for all-process consignment development and production of raw material drugs necessary for clinical trials of new drugs. With this contract, the drug substance CDMO business is in full swing and plans to expand its position in advanced markets.
Taeyoung Kim, CEO of Kyongsang Pharmaceutical, said, “With this consignment production and export contract, Kyongsang Pharmaceutical’s R&D and production capabilities have been proven in the global market.” said.
Chong Kun Dang(178,500 -4.29%)Kyungsang Pharmaceutical, a subsidiary of the group, is a pharmaceutical company specializing in drug substance manufacturing with large-scale production facilities in Asan, Chungcheongnam-do. It produces various raw material drugs such as anticancer drugs, sepa-based antibiotics, highly active drugs, and general drugs. Recently, it is expanding its scope to finished drug sales, medical device business, and animal health care business.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution